Jayne Dixon Weber

Ms. Jayne Dixon Weber


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2019 in Brain Sciences
Verified
Journal Article
Open access
PDF file
JWJayne Dixon Weber
Jayne Dixon Weber
ESElizabeth Smith
Elizabeth Smith
EBElizabeth M. NA Berry-Kravis
Elizabeth M. NA Berry-Kravis
DCDiego Cadavid
Diego Cadavid
DHDavid Hessl
David Hessl
CECraig A. Erickson
Craig A. Erickson
To date, there has been limited research on the primary concerns and treatment priorities for individuals with fragile X syndrome (FXS) and their families. The National Fragile X Foundation in collaboration with clinical investigators from industry and academia constructed a survey to investigate the main symptoms, daily living challenges, family impact, and treatment priorities for individuals with FXS and their families, which was then distributed to a large mailing list. The survey included both structured questions focused on ranking difficulties as well as qualitative analysis of open-ended questions. It was completed by 467 participants, including 439 family members or caretakers (family members/caretakers) of someone with FXS, 20 professionals who work with a person with FXS, and 8 individuals with FXS. Respondents indicated three main general areas of concern: Anxiety, behavioral problems, and learning difficulties. Important differences were noted, based on the sex and age of the individual with FXS. The results highlight the top priorities for treatment development for family members/caretakers, as well as a small group of professionals, and an even smaller group of individuals with FXS, while demonstrating challenges with “voice of the patient” research in FXS.

15 December 2018 in Brain Sciences
Verified
Journal Article
Open access
PDF file
CECraig A. Erickson
Craig A. Erickson
WKWalter E. Kaufmann
Walter E. Kaufmann
DBDejan B. Budimirovic
Dejan B. Budimirovic
ALAve Lachiewicz
Ave Lachiewicz
BHBarbara Haas-Givler
Barbara Haas-Givler
EBElizabeth M. NA Berry-Kravis
Elizabeth M. NA Berry-Kravis
Preclinical studies using animal models of fragile X syndrome have yielded several agents that rescue a wide variety of phenotypes. However, translation of these treatments to humans with the disorder has not yet been successful, shedding light on a variety of limitations with both animal models and human trial design. As members of the Clinical Trials Committee of the National Fragile X Foundation, we have discussed a variety of recommendations at the level of preclinical development, transition from preclinical to human projects, family involvement, and multi-site trial planning. Our recommendations are made with the vision that effective new treatment will lie at the intersection of innovation, rigorous and reproducible research, and stakeholder involvement.

16 September 2022 in Genes
Verified
Journal Article
Open access
PDF file
RLReymundo Lozano
Reymundo Lozano
TTTalia Thompson
Talia Thompson
JWJayne Dixon Weber
Jayne Dixon Weber
CECraig A. Erickson
Craig A. Erickson
EBElizabeth M. NA Berry-Kravis
Elizabeth M. NA Berry-Kravis
DHDavid Hessl
David Hessl
Caregiver reports, clinical observations, and diagnostic assessments indicate that most individuals with fragile X syndrome experience high levels of chronic anxiety. However, anxiety is a challenging endpoint for outcome measurement in FXS because most individuals cannot reliably report internal emotional or body states. A comprehensive survey of the presence, frequency, and duration of anxiety-related symptoms and questions to elicit open-ended responses was completed by caregivers of 456 individuals with FXS, ages 2–81 years (87 female, 369 male) and 24 female and 2 male FXS self-advocates ages 15–66 years. Caregivers reported classic behavioral indicators of anxiety, such as avoidance, irritability, motor agitation, and physiological symptoms, as well as behavioral features in FXS such as repetitive behavior, aggression, and self-injury. Self-advocate accounts largely paralleled caregiver data. Factor analyses yielded four factors: (1) increased irritability, aggression, and self-injury; (2) increased physical movement, nervous activity, and restlessness; (3) physical and physiological features of anxiety; and (4) internalizing and gastrointestinal symptoms. Caregivers are capable of observing and reporting behaviors that are valid indicators of anxious states that are usually reported in self-report standardized assessments. These results support the development of an anxiety measure for FXS that minimizes problems with rater inference.

6 September 2022 in Genes
Verified
Journal Article
Open access
PDF file
MMMadison Maertens
Madison Maertens
HSHailey Arin Silver
Hailey Arin Silver
JWJayne Dixon Weber
Jayne Dixon Weber
HRHilary Rosselot
Hilary Rosselot
RLReymundo Lozano
Reymundo Lozano
Cannabidiol (CBD) is a non-intoxicating chemical in cannabis plants that is being investigated as a candidate for treatment in Fragile X Syndrome (FXS), a leading known cause of inherited intellectual developmental disability. Studies have shown that CBD can reduce symptoms such as anxiety, social avoidance, hyperactivity, aggression, and sleep problems. This is a qualitative study that utilized a voluntary-anonymous survey that consisted of questions regarding demographics, medical information, the form, type, brand, dose, and frequency of CBD use, the rationale for use, the perception of effects, side effects, and costs. The full survey contained a total of 34 questions, including multiple-choice, Likert-scale, and optional free-response questions. This research revealed that there are a wide range of types, brands, and doses of CBD being administered to individuals with FXS by their parents and caregivers. There were many reasons why CBD was chosen, the most common ones being that respondents had heard positive things about CBD from members of the community, the perception that CBD had fewer side effects than other medications, and because respondents felt that CBD was a more natural substance. Most of the parents and caregivers who responded agreed that CBD improved some of the symptoms of FXS and made a positive difference overall. CBD has the therapeutic potential to help relieve some FXS symptoms. Future research is necessary to understand the benefits of CBD in FXS.